Repligen (RGEN) Tops Q3 EPS by 14c, Raises FY Guidance
Get Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Net (loss) income: 1.16M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q3 EPS of $0.78, $0.14 better than the analyst estimate of $0.64. Revenue for the quarter came in at $178.2 million versus the consensus estimate of $163.97 million.
GUIDANCE:
Repligen sees FY2021 EPS of $2.86-$2.91, versus the consensus of $2.68. Repligen sees FY2021 revenue of $655-665 million, versus the consensus of $640.6 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share